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Abstract 
Hemin binds to isolated low-density lipoprotein (LDL) and thereby triggers LDL oxidation. In this study we investigated whether 
heroin can get together with LDL under physiological conditions. The relative affinity of three blood components o free hemin was as 
follows: RBCM < LDL < albumin. At physiological molar ratio of LDL/albumin all the hemin was bound to albumin. In molar excess 
of albumin over hemin, existing even under pathological conditions, albumin served as an efficient antioxidant for the plasma 
heroin-induced LDL oxidation. RBCM-embedded hemin, unlike plasma hemin, affected LDL: the mobile hemin was transferred from 
RBCM to LDL in the absence of albumin, whereas in the presence of albumin most of the mobile hemin finally reached the albumin but 
partially via LDL. Thus, a transient hemin is built up in LDL. This transient hemin triggered LDL oxidation which was not inhibited but 
rather promoted by albumin. The involvement of albumin in this oxidation was explained by its acting as a pump thereby increasing the 
transient hemin in LDL. It is suggested that increased membrane hemin level as in hemoglobinopathies and/or excess LDL in 
dyslipidemia provide conditions for hemin-induced LDL oxidation. 
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I. Introduction 
Oxidative modification of low-density lipoprotein (LDL) 
is thought o play an important role in the development of 
atherosclerosis. A yet unresolved question is what agents 
trigger the oxidative process [1]. LDL oxidation has been 
studied extensively in vitro using mostly copper as the 
oxidative promoter [2-5]. As copper is unlikely to exist in 
a free form in vivo [6] and correlation between copper- 
oxidized LDL and risk of atherosclerosis could not always 
be demonstrated [7], it appears that oxidation of LDL 
depends not only on the particle composition but also on 
the biochemical method employed for oxidation. In light of 
the above, to apply conclusions from in vitro findings to 
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human pathophysiology, the best choice should be to 
employ an in vivo available oxidant. 
Recent studies by Vercellotti et al. showed that free 
hemin was also a mediator of LDL oxidation, even more 
active than the porphyrin-lacking iron [6]. We reported 
lately that free hemin was more active than copper and, 
unlike copper, the main product of the hemin-induced LDL 
oxidation was a covalently cross-linked apolipoprotein B- 
100 (apo B) [8]. Since there is only one protein molecule 
per LDL particle, this cross-linking would end up in 
aggregation of LDL, a precondition for atherosclerotic 
plaque formation [4]. As free heroin is a blood component, 
and increased hemin is associated with many pathological 
states, it is highly probable that heroin serves as a physio- 
logical oxidant. The arising quesUon is whether hemin can 
get together with LDL under phx dological conditions and 
if so can it induce LDL oxidatio~ ?
Hemoglobin and free hemin at !~ear in plasma following 
intravascular hemolysis. To protc t the system from oxida- 
tive damage, the hemoglobin is -emoved by haptoglobin 
while elimination of the free h~ nin from circulation in- 
volves albumin and hemopexin [ 10]. Because binding of 
hemin leads to the removal of mopexin (but not albu- 
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rain) [l I], its plasma level becomes negligible in disorders 
resulting in elevation of free hemin [12]. Nevertheless, 
albumin, the main plasma protein, is always available at 
concentrations high enough to bind circulating hemin, 
thereby serving as the plasma hemin reservoir. 
In recent years it became clear that globin-free hemin 
can also be released into circulation directly from its major 
depot, the red cell, without cell lysis [13]. The first step in 
this process involves the intercalation of the globin-free 
hemin into the erythrocyte membrane. The membrane-as- 
sociated hemin was found to be elevated in pathological 
cases like severe hemoglobinopathies, sickle cell anemia 
and thalassemia, in which the globins tend to release 
hemin [13,14]. The second step, namely clearance of the 
membrane from hemin, was suggested to be carried out by 
albumin and hemopexin [13,15]. As a hydrophobic lipopro- 
tein, LDL may also play a role in hemin clearance, but this 
aspect was not considered yet. Supporting evidence for 
LDL involvement in hemin transport is provided by our 
recent finding that hemin associates with isolated LDL [8]. 
Lipoproteins were also shown to be the main blood carri- 
ers of porphyrins administered to patients for phototherapy 
[16]. 
It has been documented that red blood cell membrane 
(RBCM) is constantly in a dynamic equilibrium with other 
blood constituents [17]. A massive exchange of phospho- 
lipids, cholesterol, and steroids between lipoproteins and 
RBCM was observed at physiological temperature of 37°C, 
when phospholipids are fluid [18]. Based on the above, we 
hypothesized that free hemin may also be exchanged be- 
tween RBCM and LDL and thereby LDL serves as a 
transient station in hemin transport from RBCM to plasma 
proteins. If LDL is one of the stations in hemin transport, 
it may be exposed to hemin-induced oxidation in vivo. In 
the current study we searched for the possible transport of 
hemin from RBCM to LDL in the presence and absence of 
albumin and the involvement of this transient hemin in 
LDL oxidation. 
2. Materials and methods 
2.1. Chemicals 
5-Dimethylaminonaphthalene-l-sulfonyl (dansyl) chlo- 
ride, human serum albumin (essentially globulin free), 
bovine hemin, phenylmethylsulfonyl fluoride (PMSF) and 
general chemicals were purchased from Sigma. Monobro- 
mobimane (mBBr) was purchased from Calbiochem. Hy- 
drogen peroxide was obtained from Merck. Chemicals for 
sodium dodecylsulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) were purchased from Bio-Rad. 
2.2. Isolation of LDL and RBCM 
Blood of healthy donors was drawn into EDTA-Na 4 
containing tubes (final concentration: 1 mg/ml). The iso- 
lated plasma was supplied with 15 /.*g/ml PMSF to 
prevent proteolysis. LDL (d= 1.019-1.063 g/ml) was 
isolated from the plasma by sequential ultracentrifugation 
followed by an extensive dialysis (3 changes within 24 h) 
against deoxygenated phosphate (10 mM) -buffered saline 
(PBS) (pH 7.4) at 4-8°C [19]. LDL preparation was stored 
under N 2 for up to 7 days at 2-4°C. Erythrocytes were 
washed three times with PBS and lysed by ice-cold 5 mM 
phosphate buffer (pH 8.0). After centrifugation at 30000 
× g for 30 min followed by 3 washes, open red blood cell 
ghosts were obtained [20]. These ghosts were resealed by 
incubation with 9 volumes of a resealing buffer (5 mM 
phosphate, 145 mM NaCI, 0.2 mM CaCI 2, 2 mM MgC12, 
pH 7.4) for I h at 37°C [15]. These ghosts were referred to 
as RBCM throughout this paper. 
To receive RBCM-embedded hemin (RBCM-H), we 
incubated heroin and RBCM at the ratio of 5:0.6 
(/xM: p,g/ml, respectively), which ensures complete hemin 
binding [21]. Indeed after centrifugation of this suspension 
(30000 × g for 30 min), a small hemin fraction (4.5%) 
was found in the supernatant. The high light scatter of this 
supernatant revealed that this hemin fraction was also 
membrane-associated, probably with small membrane vesi- 
cles. To prepare RBCM-H with hemin bound only to the 
membrane surface, the mixture of RBCM and hemin was 
incubated at 37°C for 5-10 min followed by storage on 
ice. To prepare RBCM-H with hemin equilibrated through- 
out the membrane, the mixture was incubated at 37°C for 2 
h (long-term incubation) [15]. 
2.3. Fluorescent labelling of RBCM, LDL and albumin 
Samples of RBCM, LDL (4-6 mg/ml each) and albu- 
min (32 mg/ml) were labelled with covalently bound 
fluorescent dyes: either with dansyl chloride or mBBr 
[15,22]. Emission spectra of the labelled components were 
taken and the relative polarity of the fluorophore nviron- 
ments within the blood components was estimated accord- 
ingly [23]. Dansylation procedure: each blood component 
was 10-fold diluted with 5 mM NaHCO3-containing saline. 
Dansyl chloride in acetone was added to a 70 p~g/ml final 
concentration (less than 1% acetone in sample). The mix- 
ture was incubated for 45 min on ice with stirring followed 
by dialysis (two changes) against PBS to remove non-bound 
fluorescent dye. Polarity of dansyl fluorophore nviron- 
ments differed among components in the following order: 
RBCM (504 nm emission maximum) > LDL (501 nm) > 
albumin (492 nm). The fluorescence intensity of dansy- 
lated blood components was measured in further experi- 
ments at excitation/emission wavelength of 350/500 nm, 
respectively, mBBr labelling procedure: each blood com- 
ponent was 5-fold diluted with PBS, mBBr in acetonitril 
was added to a 250 /zM final concentration (less than 1% 
acetonitril n sample). The mixture was incubated for 1 h 
at 37°C followed by dialysis (two changes) against PBS. 
Polarity of mBBr fluorophore nvironments differed among 
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blood components in the following order: RBCM (471 nm 
emission maximum) > albumin (465 nm)> LDL (451 nm). 
The fluorescence intensity of mBBr-labelled blood compo- 
nents was measured in further experiments at 
excitation/emission wavelength of 400/460 nm, respec- 
tively. 
Unless otherwise stated, all the experiments with blood 
components were made at their ratio of 2:1:50 
RBCM/LDL/albumin, mg/ml  respectively, which is in 
the physiological range. Fluorescence intensity of a label 
bound to one of the blood components (e.g., RBCM) is 
abbreviated in the form of 'RBCM fluorescence', likewise 
for LDL and albumin appearing later in the text and 
figures. 
2.4. Interaction of hemin with RBCM, LDL and albumin 
Association of hemin and its dissociation from RBCM, 
LDL and albumin were followed at 37°C by quenching 
and recovery of fluorescence intensity, respectively [15]. 
Low concentrations of hemin were used to avoid trivial 
quenching of the fluorophores. Whenever hemin concen- 
trations were increased, the trivial contribution to the 
changes in fluorescence intensity were deducted. Because 
fluorescence intensity is not always linear with concentra- 
tion, calibration curves of fluorescence intensity versus 
distinct hemin concentrations were carried out to enable 
the quantitation of bound/dissociated heroin. 
2.5. Oxidation of LDL 
LDL (600 tzg/ml) was oxidized by hemin in the 
presence of 10 /zM H202 for 3 h at 37°C. Hemin was 
added to LDL samples either in a free form (heroin stock 
solution in 80% DMSO, less than 1% DMSO in sample) or 
bound to either RBCM or albumin. 
2.6. Analytical procedures 
Fluorescent measurements were performed with an 
SLM-Aminco 8000 Spectrofluorimeter (SLM Instruments). 
Absorption spectra were measured with a Diode Array 
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Fig. 1. Transport of hemin from RBCM to LDL and albumin. RBCM, 6 /zg/ml; LDL, 3 /xg/ml; albumin, 140 /zg/ml; hemin, 0.1 /~M. A and B, 
dansylated RBCM. A: RBCM was treated with hemin and then LDL (solid line) or albumin (dotted line) were added. B: LDL (solid line) or albumin 
(dotted line) were added to RBCM and then hemin was added. C and D, dansylated LDL. C: LDL was treated with hemin and then RBCM was added. D: 
RBCM was added to LDL and then hemin was added. 
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Spectrophotometer HP 8452A (Hewlett-Packard). Concen- 
trations of RBCM, LDL, and albumin were expressed as 
protein concentrations as determined by the method of 
Lowry [24]. Hemin concentration was measured in 80% 
DMSO using e403 = 1.7. 105 M lcm-l [25]. The protein 
patterns were followed by SDS-PAGE [26] with /3-mer- 
captoethanol. Gel slabs were discontinuous, bilayers of 6% 
(2/3 of the length) and 12% (1/3) acrylamide. Slabs were 
stained using Coomassie brilliant blue R-250. Gel den- 
sitometry was performed using TLC Scanner II (Camag). 
Thiobarbituric acid reactive substances (TBARS) were de- 
termined as described in Ref. [6]. 
3. Results 
3.1. The relative affinity of heroin for RBCM, LDL, and 
albumin 
In Fig. 1 we present data obtained with either dansy- 
lated RBCM or LDL. LDL added a few minutes after 
association of hemin with RBCM caused a partial release 
of the hemin from the membrane (Fig. 1A). The ability of 
LDL to extract heroin from RBCM resembles that found 
for albumin [13]. Our results showed that at physiological 
ratio albumin was more efficient than LDL (Fig. 1A). 
Under the same conditions, in the presence of either LDL 
or albumin, binding of hemin with RBCM was completely 
prevented (Fig. 1B). RBCM was unable to cause any 
dissociation of hemin from LDL (Fig. 1C). Prior addition 
of RBCM to LDL could not interfere with hemin-LDL 
binding (Fig. 1D). 
We next studied the dependence of hemin transport 
from RBCM to LDL on its location. Hemin was added to 
suspensions of dansylated RBCM under conditions either 
leaving all the hemin in the outer membrane leaflet or 
allowing its distribution throughout the membrane (see 
Section 2) [15]. LDL was then added to the mixtures and 
time-dependent changes of fluorescence intensity were fur- 
ther followed (Fig. 2). As seen, 52% of the hemin associ- 
ated with RBCM surface could be extracted by LDL, but 
when hemin was equilibrated between both membrane 
leaflets, only 15% were LDL extractable. 
Addition of albumin to LDL a few minutes after hemin 
caused complete dissociation of the LDL-bound hemin 
(Fig. 3A). Prior admixing of LDL with albumin practically 
prevented binding of hemin to LDL (Fig. 3B). Binding of 
hemin to albumin was unaffected by RBCM, but LDL 
caused partial dissociation of the albumin-bound hemin 
(Fig. 3C). The time course of fluorescence quenching 
showed a fast phase followed by a slower one (Fig. 3C), 
reflecting the presence of high and lower affinity sites on 
albumin for hemin [27,28]. From the quenching pattern of 
albumin by hemin in the presence of RBCM (Fig. 3D, 
dotted), we judged that RBCM competed only for albumin 
lower affinity sites. LDL competition for hemin was differ- 
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Fig. 2. Dependence of the heroin transfer from RBCM to LDL on the 
time of hemin preincubation with the membrane. RBCM, 12 /zg/ml; 
LDL, 7 /xg/ml; hemin, 0.25 p.M. Dansylated RBCM was treated with 
heroin for 6 min (upper scale, solid line) and for 120 min (lower scale, 
dotted line after axis break), and then LDL was added. 
ent: LDL competed for both high and low affinity sites of 
albumin (compare Fig. 3C and solid line in Fig. 3D). 
The results of Figs. 1 and 3 indicate that the affinity of 
hemin to the blood components differed in the following 
order: RBCM < LDL < albumin. Thus, it turns out that 
RBCM-embedded heroin is expected to associate finally 
with albumin. 
3.2. Hemin distribution among the three blood components 
In this section we studied hemin distribution among 
RBCM, LDL, and albumin present simultaneously. To find 
out if LDL is involved in transport of mobile hemin from 
RBCM-H to the albumin, RBCM was shortly incubated 
with hemin followed by addition of dansylated albumin 
either alone or together with LDL. LDL/albumin ratio 
was varied by changing albumin concentration. In all 
reaction mixtures the fluorescent signal appearing after 
addition of the dansylated albumin decayed with time. The 
rate of fluorescence decay in presence and absence of LDL 
differed, indicating that LDL was involved in the heme 
transport (Fig. 4A, upper and lower curves, respectively). 
Apparently, the kinetic difference resulted from a slower 
rate of decay in the LDL-containing sample during the first 
reaction stage. Also, the initial fluorescence intensity 
(measured only after mixing time) was consistently higher 
in the presence than in the absence of LDL. To elucidate 
LDL contribution, a difference curve was drawn (Fig. 4B), 
reflecting the hemin fraction which was detached from the 
membrane but was delayed in passing to albumin. This 
presents a time-dependent pool of hemin in LDL resulting 
from a difference in the rates of its influx from RBCM and 
efflux to albumin. Therefore, the ascending part of the 
difference curve was interpreted as representing a higher 
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influx than effiux rate in the single pulse type experiment, 
while the descending represented the reverse: a higher 
efflux rate. Thus, the ratio of ascending to descending 
amplitudes, AF r = (Fma x - Fo)/(Fma ~ - E~), is a function 
of the amount of hemin transferred through LDL. The 
dashed line in Fig. 4B represents the difference curve of 
twice the former LDL/albumin ratio. AF r dependence on 
LDL/albumin molar ratio is presented in the inset of Fig. 
4B. The chosen LDL/albumin ratios cover the range from 
ratio present in normal healthy donors to that present in 
pathological cases of either elevated LDL or hypoalbu- 
minemia states. In addition to information achieved using 
labelled albumin (Fig. 4), evidence for the transient resi- 
dency of hemin in LDL is presented in Fig. 5, this time 
from the LDL point of view. Addition of RBCM-H con- 
taining surface-bound heroin to the dansylated LDL caused 
a fast quenching of the LDL fluorescence (Fig. 5, dotted 
line). Addition of the same RBCM-H to admixture of LDL 
and albumin resulted in a two-phase time course pattern of 
fluorescence changes: a fast decrease followed by a slow 
recovery of the fluorescence intensity (Fig. 5, solid trace). 
The observed fluorescence changes were interpreted as a 
combination of a fast transfer of hemin from RBCM to 
LDL (as in the absence of albumin), followed by a slower 
transfer of the LDL-associated hemin from LDL to albu- 
min. 
3.3. The effect of  labelling on the characteristics of  the 
blood components 
Since LDL is known to be modified by blocking free 
amino groups [5], it was of importance to find out whether 
the dansylation did not affect the properties of the labelled 
components. Therefore all the experiments were repeated 
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using mBBr, a specific free SH-groups label [22] which 
does not affect the charge and is expected to have a 
different location from dansyl on the LDL [15,22]. It was 
found that the results regarding hemin transfer between 
RBCM, LDL and albumin were probe-independent (data 
not shown), leading to the conclusion that, at least as far as 
heine distribution is concerned, the labels did not change 
the intrinsic properties of these blood components. 
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hemin-containing RBCM: effect of LDL. LDL, 7 ~g/ml ;  RBCM-H (13 
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the difference obtained at lower albumin concentration (68 /xg/ml). F 0, 
the fluorescence intensity observed immediately following mixing; Fma x , 
the maximal fluorescence intensity; E~, the fluorescence intensity after 
signal stabilization. B: Inset: The dependence of the AF r on the molar 
ratio of LDL/albumin. LDL, 7 /zg/ml; RBCM-H (13 /xg/ml RBCM, 
0.7 /xM hemin); albumin: 34-270 /.Lg/ml. The fluorescence ratio AFt 
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Fig. 5. The time course of the changes in LDL fluorescence induced by 
hemin-containing RBCM: effect of albumin. RBCM-H (13 /xg/ml 
RBCM, 0.7/xM hemin); LDL, 7/xg/ml;  albumin, 350 fzg/ml. RBCM-H 
was added to dansylated LDL alone (dotted line) and in the presence of 
albumin (solid line). 
3.4. Can membrane-associated h min trigger oxidation of 
LDL ? 
As LDL-bound hemin can trigger LDL oxidation [6,8], 
it was of further interest o assess the ability of RBCM-H 
to induce oxidation of LDL. Fresh LDL samples were 
mixed with hemin alone or together with RBCM and/or 
albumin and further incubated at 37°C for 3 h under 
oxidative conditions (10 /~M H 202)" Representative data 
are shown in Fig. 6: incubation of LDL with 10 /xM 
hemin caused complete disappearance of the LDL protein 
from its original position. The markedly slow migrating 
modified protein was interpreted as a covalent cross-lin- 
king of apo B (compare lanes 1 and 2 in Fig. 6) [8]. The 
fact that the total amount of protein observed in the lanes 
of treated samples was reduced relative to the control 
suggested that some aggregates failed to enter the gel. An 
appreciable LDL oxidation was found when as low as 1.5 
/zM hemin was directly added to LDL (Fig. 6, lane 3). 
This hemin amount relates to the 15% hemin extractable 
from RBCM by LDL, found earlier (Fig. 2, lower curve). 
The fraction of residual apo B monomer serving as a 
monitor for protein oxidation and TBARS as a measure of 
lipid oxidation are presented in Fig. 6B,C. As seen, apo B 
monomer was reduced concomitantly with increased 
TBARS values. In another sample 10 /xM hemin was 
intercalated into RBCM by incubation for 2 h at 37°C. 
This sample was further centrifuged for 30 min at 30 000 
× g, separating the supernatant from the membrane pellet 
(RBCM-H). LDL incubated with RBCM-H was found to 
be oxidized (Fig. 6, lane 4) although to a lesser extent han 
did its admixture with 1.5 /xM hemin (lane 3). The super- 
natant as well as RBCM alone had no effect on both LDL 
protein and lipids (compare lanes 5 and 6 with i). LDL 
samples which contained 10 /zM albumin in addition to 
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RBCM-H, developed more oxidative products than the 
albumin-lacking ones (lane 7 as compared to 4). It was 
found that under the above conditions 25% hemin was 
transferred from RBCM-H to the albumin (data not shown). 
A mixture of 10 /zM albumin with 2.5 /zM hemin was 
inactive as an LDL oxidant (lane 8). 
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Fig. 6. Oxidation of LDL by hemin-containing RBCM. LDL (600 mg/ml) was incubated at 37°C for 3 h in presence of 10 /zM HzO 2 with the following 
compounds: alone (lane 1): 10 /zM hemin (lane 2); 1.5 /xM hemin (lane 3); RBCM-H (1.2 mg/ml RBCM, 10 /zM hemin) (lane 4); 1.2 mg/ml RBCM 
(lane 5); supernatant (lane 6); RBCM-H + 10 /zM albumin (lane 7); 2.5 /zM hemin + 10 /zM albumin (lane 8). A: SDS-PAGE protein patterns. The 
numbers on the left-hand side relate to the molecular weights (kDa) of the reaction proteins: 67, albumin; 240 and 260, spectrin; 550, apo B monomer. The 
marked zone above the position of the apo B monomer (D includes the different size aggregates of apo B formed. All proteins of 260 kDa and below refer 
mostly to the RBCM proteins, albumin monomer and aggregates. B: Amount of apo B monomer. The amount of protein was assessed by gel densitometry. 
The minor amount of degraded apo B which appeared below the monomer position could not be resolved from the adjacent RBCM and albumin protein 
bands. Thus, the relative amount of residual apo B monomer was calculated as M/(M + C), where M = the amount of protein in the apo B monomer 
position and C = the amount of cross-linked apo B in the bands appearing above the monomer. C: The amount of oxidized lipids. The amount of lipids 
peroxidation products was determined by quantitation of the TBARS in each sample. 
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4. Discussion 
Since globin-free hemin appears in both RBCM and the 
plasma, we studied whether LDL has any contact with 
hemin in presence of physiological ratios of RBCM and 
albumin, the abundant protein in plasma which binds 
hemin [27,28]. Two options for exposure of LDL to hemin 
were considered in the current study: (1) by direct associa- 
tion with the globin-free hemin available in plasma follow- 
ing hemolysis and (2) by interchange of globin-free hemin 
between RBCM and LDL. Although hemin binds with 
isolated LDL [8], this study proved that under physio- 
logical ratio of LDL/albumin, hemin was solely albumin 
bound (Fig. 3A,B). Based on various studies, albumin was 
stated as a general antioxidant [29]. However, a recent 
study using hemin equimolar to albumin suggested that, 
unlike hemopexin, albumin cannot prevent he hemin-tri- 
ggered LDL oxidation [6]. Nevertheless, albumin is avail- 
able in plasma at the high concentration of 600 /xM, thus 
expected to be always in large excess of the limited free 
hemin amounts. Our study indicated that a four-fold excess 
of albumin over hemin could already suffice to inhibit 
completely the hemin oxidative effect (Fig. 6, lane 8). 
Thus, even in the absence of hemopexin, albumin serves as 
an antioxidant preventing heroin-induced LDL oxidation in 
plasma. 
RBCM hemin relates to LDL differently from plasma 
hemin. The globin-free hemin pool in RBCM is composed 
of two categories: the loosely phospholipid-associated 
hemin which is free to pass through the membrane, and the 
strongly, protein-anchored pool that can hardly be removed 
by either albumin or hemopexin [13,15]. As LDL has been 
documented to exchange phospholipids, cholesterol and 
steroids with RBCM [17,18], we expected a similar inter- 
change of hemin between LDL and RBCM. However, our 
data definitely show that red cell membranes have a much 
lower affinity for hemin than LDL, resulting in a unidirec- 
tional flow of hemin from RBCM to LDL (Fig. 1C,D). The 
difference in protein-phospholipid location between those 
two blood components can account for the hemin mode of 
flow. In the LDL particle the apo B protein composes a
large portion of the outer surface area as opposed to the 
inner leaflet location of the RBCM proteins [22,30]. It 
should be reminded that in both RBCM and LDL, proteins 
embody the higher affinity sites. The higher LDL affinity 
for hemin probably relates to the involvement of apo B 
protein in the attraction of the mobile heroin from the 
RBCM [81. 
LDL as well as albumin can extract he mobile hemin 
from RBCM when added separately. As it was found that 
albumin binds hemin with higher affinity than LDL (Fig. 
3A,B), one may expect hat in presence of the two, hemin 
will transfer directly to albumin avoiding the LDL. Our 
results show a more complicated system: the data pre- 
sented in Figs. 4 and 5 clearly indicate that even when all 
hemin eventually binds to albumin, some is transferred 
through LDL, referred to as a transient hemin pool. The 
size of this pool depended on the LDL/albumin ratio. 
Which variations in LDL/albumin ratio are expected in 
vivo? LDL concentration range screened in population was 
0.6-1.6 mg apo B /ml  [31]. Considering albumin concen- 
trations as 35-55 mg/ml  [32], the normal range of 
LDL/albumin molar ratio is calculated as (0.16-0.68). 
10 -2 . The concentration of albumin is often decreased at 
pathological situations uch as inflammation or cancer, as 
well as following surgical treatment and medication [32], 
while LDL concentration may be increased up to 3.3 
mg/ml  in hyperlipidemia [33]. Under the above-mentioned 
states the LDL/albumin ratio may increase by more than 
10 times. Fig. 5 shows that some hemin transfers through 
LDL even under the normal physiological conditions 
(LDL/aibumin = 0.35.10-2).  The inset in Fig. 4 shows 
that upon an 8-fold increase in LDL/albumin ratio (re- 
flecting the change from normal to pathologic onditions), 
the transient LDL hemin pool (presented by AFr) is in- 
creased 100-fold. In addition to the increased transient 
pool, a small fraction of the incoming hemin is actually 
retained in the LDL particle, best observed at the patholog- 
ical LDL/albumin ratio of 1.4. 10 2 (dashed line in Fig. 
4B, F~ > 0). Under conditions of the upper limit of normal 
LDL/albumin ratio (0.7- 10 2) hemin does not accumu- 
late in LDL (solid line in Fig. 4B, F~ = 0). 
While we performed one pulse experiments, hemin 
constantly accumulates in RBCM in vivo [13]. At least a 
part of this hemin pool transfers to LDL (and some is 
retained) during the several days period of erythrocyte and 
LDL coexistence in blood. A high hemin level would be 
expected especially in hemoglobinopahties where RBCM 
hemin is increased [13,14]. 
Our conclusion on the transport of globin-free hemin in 
the blood via LDL is summarized schematically below (H, 
hemin; Hb, hemoglobin; gl, globin; Hx, hemopexin): 
Erythrocyte Hb
laBCM_HI__ H+gl.plasmaHb 
= l H-ALBUMIN 
Catabolism (H-Hx 4~Liver) 
In order to study the oxidative potential of RBCM-H 
under in vivo conditions, RBCM underwent a long-term 
incubation with 10 /xM hemin. The resulted RBCM-H did 
trigger LDL oxidation (Fig. 6, lane 4). Under these experi- 
mental conditions 1.5 /xM hemin passed from RBCM to 
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LDL in the absence of a lbumin (15% of 10/xM; Fig. 2), 
yet oxidated lipids and protein levels were lower than 
those produced by a direct addition of 1.5 /zM hemin to 
LDL (Fig. 6, compare lanes 3 and 4). This may be 
explained by the fact that in a direct addition, the entire 
hemin amount was available initially, while in the case of 
RBCM-H, the level of 1.5 /xM was gradually attained by a 
slow hemin transfer from RBCM to LDL (Fig. 2). Addi- 
tionally, RBCM available antioxidants (e.g., vitamin E) 
[34] could reach LDL and replenish the LDL antioxidants 
which were consumed by the hemin-triggered oxidation. 
In line with the concept that albumin is a hemin scav- 
enger, albumin was anticipated to serve as an antioxidant 
of the membrane hemin as was found for plasma hemin. 
Our results showed that this was not the case: albumin did 
not inhibit LDL oxidation induced by RBCM-H. More- 
over, its presence even increased the level of oxidative 
products (Fig. 6, lane 7). This surprising f inding may be 
explained by a lbumin 's  role as a pump accelerating the 
transfer of RBCM hemin through the LDL particle. In- 
deed, under our experimental conditions more hemin was 
transferred to LDL in the presence of albumin than in its 
absence (2.5 and 1.5 /xM, respectively). Thus, it may be 
assumed that in the presence of a lbumin both the amount 
of heroin and the rate by which it reaches LDL are 
increased, causing an elevated hemin pool in the LDL. 
One may envisage that under repeatable vents of heroin 
passage through LDL, it may undergo heroin-triggered 
oxidation. LDL is regularly available in circulation for up 
to 8 days and longer under hypercholesterolemic condi- 
tions [33]. It is therefore likely that under both 
hemoglobinopathies and dyslipidemias an increased LDL 
oxidation by heroin will occur. 
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